Organization | Institute of Oncology Dr. Rosell (IOR)

Institute of Oncology Dr. Rosell (IOR) Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2016

NCT02841579

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Institute of oncology Dr. Rosell | Instituto Oncológico Dr Rosell

Active Ingredients

Drugs in Phase 2 Trials (7)

adc vaccine (1 trial)

atezolizumab (Tecentriq) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

egf-pti (1 trial)

gefitinib (iressa) (1 trial)

osimertinib (tagrisso) (2 trials)

Drugs in Phase 1 Trials (2)

entrectinib (Rozlytrek) (1 trial)

in01 vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Fibrosis (Phase 1)

Lung Neoplasms (Phase 2)

Pulmonary Fibrosis (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 9